Scientists are voicing concerns over the design of a French drug trial that left one participant dead and several others with severe health problems — and they are calling for more information to be released. The researchers, including those in the UK’s Royal Statistical Society (RSS), have examined a document that describes how the trial was conducted, and say that major pieces of information are still missing.
- Few details, best informed speculation
- Drug is an irreversible FAAH inhibitor
- “Off-target” effects
- Other possibilities: Drug impurities?
- Other questions: Why did the study have a placebo group?
A technique called optogenetics has transformed neuroscience during the past 10 years by allowing researchers to turn specific neurons on and off in experimental animals.
A recently developed stem cell programming technique could produce human tissue on-demand for testing new drug treatments.